23andMe announced the further expansion of the ongoing 23ME-00610 Phase 1/2a study to include an additional 30 patients with advanced neuroendocrine and ovarian cancers, above the original enrollment goals. The ongoing study has been enrolling the Phase 2a portion of the Phase 1/2a clinical trial evaluating the anti-CD200R1 monoclonal antibody since February 2023. “We are gratified by the patient and investigator enthusiasm with this clinical trial, that allows us to continue enrolling additional patients to better understand the potential for our anti-CD200R1 program,” said Jennifer Low, MD, PhD, Head of Therapeutics Development, 23andMe. “We look forward to evaluating this new data as it emerges, in order to plan for the future of this program.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ME:
- 23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
- 23andMe expects tp incur $1M-$2M in expenses from data breach
- 23andMe price target lowered to 90c from $1.75 at Citi
- 23andMe price target lowered to $3 from $5 at TD Cowen
- 23andMe launches Total Health, a new health membership